Opdivo (nivolumab) is a prescription drug approved to treat non-small cell lung cancer (NSCLC). Opdivo is available only as a brand-name medication. It’s not available in a generic version. Opdivo ...
AU-007, combined with Opdivo and low-dose aldesleukin, is being evaluated in a phase 2 cohort for second-line melanoma treatment. Previous trials showed AU-007's early antitumor activity and ...
Bladder, kidney, and other urologic cancers Colorectal and other GI cancers Head and neck cancer Melanoma and other skin cancers Respiratory and thoracic cancers Nivolumab is a human immunoglobulin G4 ...
The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric ...
Opdivo and Yervoy combination improves median OS to 23.7 months versus 20.6 months with Lenvima or Nexavar in uHCC patients. The combination shows a higher overall response rate of 36% compared to 13% ...
Bristol Myers Squibb BMY announced that the FDA will now decide on the biologics license application (BLA) for the subcutaneous formulation of Opdivo (nivolumab) on Dec 29, 2024. The subcutaneous ...
Bristol Myers Squibb BMY announced that it has obtained FDA approval for the label expansion of Opdivo (nivolumab) plus Yervoy (ipilimumab). The regulatory body approved Opdivo plus Yervoy as a ...
Opdivo’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology and includes a broad range of clinical trials across all phases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results